Bharat Gupta
Internal Medicine · Rochester, NYNPI 1992749410
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.0%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Johnson & Johnson at 43.3% of the total. Reporting peaked in 2019 at $19,652 and has fallen 99.4% since, to $125 in 2025. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 599 payments — averaging $52.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$14K
- Amgen$4K
- Sanofi-aventis U.S. LLC$3K
- GSK$2K
- AbbVie$2K
- Pfizer$1K
- plus $6K from 21 others
What the payments were for
- Consulting fees$1,9266%
- Speaking & faculty fees$10,50033%
- Travel & lodging$1,1914%
- Food & beverage$18,03357%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 64 | $13,712 |
| Amgen | 48 | $4,125 |
| Sanofi-aventis U.S. LLC | 18 | $2,917 |
| GSK | 96 | $1,983 |
| AbbVie(2 entities) | 62 | $1,555 |
| Pfizer | 102 | $1,341 |
| Novo Nordisk | 75 | $1,322 |
| Amarin Pharma, Inc. | 27 | $924 |
| AstraZeneca | 22 | $909 |
| Lilly USA, LLC | 41 | $575 |
| E.r. Squibb & Sons, L.L.C. | 6 | $369 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $349 |
| Biogen | 2 | $255 |
| Teva Pharmaceuticals USA, Inc. | 2 | $244 |
| Novartis | 7 | $130 |
| Sunovion Pharmaceuticals Inc. | 1 | $122 |
| Esperion Therapeutics, Inc. | 1 | $122 |
| Abbott | 2 | $121 |
| Braeburn Inc. | 1 | $112 |
| Nevro Corp. | 1 | $111 |
| Genentech USA, Inc. | 6 | $102 |
| Gilead | 1 | $93 |
| Merck | 3 | $51 |
| Bayer | 2 | $39 |
| Kowa Pharmaceuticals America, Inc. | 2 | $33 |
| Dermira, Inc. | 1 | $24 |
| Eisai Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$31,656 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 18 | $1,036 |
| Atorvastatin Calcium | 43 | $600 |
| Omeprazole | 22 | $445 |
| Metoprolol Succinate | 26 | $344 |
| Amlodipine Besylate | 33 | $325 |
| Levothyroxine Sodium | 17 | $182 |
| Losartan Potassium | 11 | $167 |
| Lisinopril | 16 | $160 |
| Tamsulosin Hcl | 11 | $146 |
| Simvastatin | 12 | $84 |
| Metformin Hcl | 14 | $50 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Rochester
- David DoveEast Hampton$12.3M
- Bruce BergerBrooklyn$3.4M
- Nicholas RobinsonBuffalo$2.9M
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Scott BeegleAlbany$1.9M
- Anthony MartinezBuffalo$1.6M
- Javier MoralesGreenvale$1.3M
- Ricky HsuNew York$1M
- James UnderbergNew York$953K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.